Drug Profile

2028 zT2

Alternative Names: 2028-zT2

Latest Information Update: 08 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Wellington Zhaotai Therapies
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

07 Feb 2024 2028 zT2 is available for licensing as of 07 Feb 2024. https://www.wellingtonzhaotai.com/business-development
07 Feb 2024 Wellington Zhaotai Therapies has patent protection for CAR T-cell construct with unique, co-stimulatory domain (Wellington Zhaotai Therapies pipeline, February 2024)
07 Feb 2024 Preclinical trials in Lymphoma in New Zealand (Parenteral) (Wellington Zhaotai Therapies pipeline, February 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com